These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11109534)

  • 1. [Therapeutic effect of hepatoprotectors in experimental Reye syndrome].
    Vengerovskiĭ AI; Sukhodolo IV; Chuchalin VS; Arbuzov AG; Cherviakova MB; Mel'nik IuIu; Grishina EI; Fedoreev SA; Saratikov AS
    Eksp Klin Farmakol; 2000; 63(5):68-71. PubMed ID: 11109534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol protects against experimental induced Reye's syndrome by prohibition of oxidative stress and restoration of complex I activity.
    Abdin A; Sarhan N
    Can J Physiol Pharmacol; 2014 Sep; 92(9):780-8. PubMed ID: 25162205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of the features of Reye's syndrome in rats with 4-pentenoic acid.
    Glasgow AM; Chase HP
    Pediatr Res; 1975 Mar; 9(3):133-8. PubMed ID: 1121419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in plasma amino acids and hepatic enzymes in the 4-pentenoic acid model of Reye's syndrome.
    Hart MA; Swisher JA; Caspers ML
    Biochem Pharmacol; 1989 May; 38(10):1696-8. PubMed ID: 2730684
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of phospholipid hepatoprotective agents in experimental Reye syndrome].
    Saratikov AS; Vengerovskiĭ AI; Sukhodolo IV; Chuchalin VS; Arbuzov AG; Cherviakova MB; Burkova VN
    Biull Eksp Biol Med; 2000 Mar; 129(3):337-9. PubMed ID: 10776581
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reye's syndrome].
    Wagner-Thiessen E
    Pathologe; 1985 Jul; 6(4):220-3. PubMed ID: 3900974
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reye's syndrome--a severe complication of salicylate therapy].
    Vengerovskiĭ AI; Baturina NO; Saratikov AS
    Eksp Klin Farmakol; 2000; 63(2):76-80. PubMed ID: 10834102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encephalopathy of Reye's syndrome: a review of pathogenetic hypotheses.
    DeLong GR; Glick TH
    Pediatrics; 1982 Jan; 69(1):53-63. PubMed ID: 7033913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACTION OF L-CARNITINE, CORVITIN AND THEIR COMBINATION ON FUNCTIONAL STATE OF LIVER IN EXPERIMENTAL MODEL OF REYE SYNDROME IN RATS].
    Ghonghadze M; Antelava N; Liluashvili K; Okujava M; Pachkoria K
    Georgian Med News; 2017 Feb; (263):105-111. PubMed ID: 28452736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models of Reye's syndrome.
    Saratikov AS; Vengerovskii AI; Arbuzov AG; Chuchalin VS; Chervyakova MB; Sukhodolo IV
    Bull Exp Biol Med; 2000 Apr; 129(4):400-2. PubMed ID: 10977933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antioxidant activity of the hepatoprotector maxar in experimental diabetes].
    Ian'kova VI; Ivanova IL; Fedoreev SA; Kulesh NI
    Eksp Klin Farmakol; 2002; 65(4):33-6. PubMed ID: 12452131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periportal hepatic necrosis in Reye's syndrome. One case in a review of eight patients.
    Bentz MS; Cohen C
    Am J Gastroenterol; 1980 Jan; 73(1):49-53. PubMed ID: 7377172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvesicular fatty liver in rats with resembling Reye's syndrome induced by 4-pentenoic acid.
    Sakaida N; Senzaki H; Shikata N; Morii S
    Acta Pathol Jpn; 1990 Sep; 40(9):635-42. PubMed ID: 2260472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of 4-pentenoic acid-induced liver injury in rats by 16,16-dimethyl PGE2.
    Hidaka T; Inokuchi T; Nakamura Y; Kotegawa M; Sugiyama M; Ogura R
    Exp Mol Pathol; 1991 Oct; 55(2):135-42. PubMed ID: 1936211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of an animal model of a Reye-like syndrome caused by Margosa oil.
    Sinniah D; Schwartz PH; Mitchell RA; Arcinue EL
    Pediatr Res; 1985 Dec; 19(12):1346-55. PubMed ID: 4080457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reye's and Reye's-like syndromes.
    Pugliese A; Beltramo T; Torre D
    Cell Biochem Funct; 2008 Oct; 26(7):741-6. PubMed ID: 18711704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Citrulline for Reye's syndrome.
    N Engl J Med; 1974 Aug; 291(8):421. PubMed ID: 4855508
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of silymarin and its combination with succinic acid on brain bioenergetics in rats with experimental inhibition of beta-oxidation of fatty acids].
    Vengerovskiĭ AI; Khazanov VA
    Eksp Klin Farmakol; 2007; 70(2):51-5. PubMed ID: 17523453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reye's syndrome: management of hyperammonemia by essential amino acid-ketoacid substitution].
    Békési A; Kerepesi T; Szombathy G; Karsai T
    Orv Hetil; 1988 Jan; 129(3):141-2, 145. PubMed ID: 3353110
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the possible role of glucose, carnitine, coenzyme Q10 and steroids in the treatment of Reye's syndrome using the margosa oil animal model.
    Sinniah D; Sinniah R; Baskaran G; Pathmanathan R; Yamashita F; Yoshino M
    Acta Paediatr Jpn; 1990 Aug; 32(4):462-8. PubMed ID: 2288230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.